Human Chondrocytes Search Results


93
ATCC human chondrocyte cell line chon 001
Human Chondrocyte Cell Line Chon 001, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/Human+Chondrocytes/CHON-001%3B+chondrocyte%3B+Human/pm41609406-28-0-5
Average 93 stars, based on 1 article reviews
human chondrocyte cell line chon 001 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

91
StemBioSys chondrocytes
Chondrocytes, supplied by StemBioSys, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/Human+Chondrocytes/Human+Chondrocytes-+Donors+with+Osteoarthritis+50-70+Years+of+Age/pm35030290-356-0-2
Average 91 stars, based on 1 article reviews
chondrocytes - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

94
Cell Applications Inc chondrocyte growth medium
Microfluidic platform and chip layout for dynamic <t>chondrocyte</t> culture under gravity‐driven flow. (A) Photograph of the microfluidic chip with reservoirs filled with culture medium, illustrating the assembled device used for experiments. (B) Schematic representation of the microfluidic chip layout showing an array of 24 culture units. Each unit comprises two culture medium reservoirs connected by four microchannels with varying width and height, subdivided into regions I–III to generate spatial gradients of fluid shear stress under gravity‐driven flow conditions.
Chondrocyte Growth Medium, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/Human+Chondrocytes/Human+Chondrocyte+Media/pmc13690009-83-24-30
Average 94 stars, based on 1 article reviews
chondrocyte growth medium - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

95
PromoCell chondrocyte culture
Figure 5. Healthy and pathological cartilage and tendon-on-a-chip models. A) Schematic representation of the OoC configuration to generate healthy and pathological musculoskeletal models. Specific cells are embedded within a representative matrix. This OoC further allows the perfusion of bioactive compounds. B) Alamar blue assay indicating the increase cell activity and C) Brightfield images with culture time when using tenocytes and <t>chondrocytes.</t> D) Brightfield and immunofluorescence images of the cells embedded within the matrix before and after the treatment with IL-1𝛽. E) ELISA for the quantification of IL-6 to assess regeneration of the OoC models after the treatment with an anti-inflammatory drug (baicalein). N = 3 independent experiments in separate plates.
Chondrocyte Culture, supplied by PromoCell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/Human+Chondrocytes/Human+Chondrocytes/10__1002_slash_admt__202402080-248-30-35
Average 95 stars, based on 1 article reviews
chondrocyte culture - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

96
Cell Applications Inc t 75 flasks
Figure 5. Healthy and pathological cartilage and tendon-on-a-chip models. A) Schematic representation of the OoC configuration to generate healthy and pathological musculoskeletal models. Specific cells are embedded within a representative matrix. This OoC further allows the perfusion of bioactive compounds. B) Alamar blue assay indicating the increase cell activity and C) Brightfield images with culture time when using tenocytes and <t>chondrocytes.</t> D) Brightfield and immunofluorescence images of the cells embedded within the matrix before and after the treatment with IL-1𝛽. E) ELISA for the quantification of IL-6 to assess regeneration of the OoC models after the treatment with an anti-inflammatory drug (baicalein). N = 3 independent experiments in separate plates.
T 75 Flasks, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/Human+Chondrocytes/Major+Media/bio_rxiv__64898__2026__04__03__716316-186-4-10
Average 96 stars, based on 1 article reviews
t 75 flasks - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

94
Boster Bio rabbit anti crtac1
Figure 5. Healthy and pathological cartilage and tendon-on-a-chip models. A) Schematic representation of the OoC configuration to generate healthy and pathological musculoskeletal models. Specific cells are embedded within a representative matrix. This OoC further allows the perfusion of bioactive compounds. B) Alamar blue assay indicating the increase cell activity and C) Brightfield images with culture time when using tenocytes and <t>chondrocytes.</t> D) Brightfield and immunofluorescence images of the cells embedded within the matrix before and after the treatment with IL-1𝛽. E) ELISA for the quantification of IL-6 to assess regeneration of the OoC models after the treatment with an anti-inflammatory drug (baicalein). N = 3 independent experiments in separate plates.
Rabbit Anti Crtac1, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/Human+Chondrocytes/Human+CRTAC1+ELISA+Kit+PicoKine/pmc12912019-85-25-27
Average 94 stars, based on 1 article reviews
rabbit anti crtac1 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Cell Applications Inc human chondrocytes
Figure 5. Healthy and pathological cartilage and tendon-on-a-chip models. A) Schematic representation of the OoC configuration to generate healthy and pathological musculoskeletal models. Specific cells are embedded within a representative matrix. This OoC further allows the perfusion of bioactive compounds. B) Alamar blue assay indicating the increase cell activity and C) Brightfield images with culture time when using tenocytes and <t>chondrocytes.</t> D) Brightfield and immunofluorescence images of the cells embedded within the matrix before and after the treatment with IL-1𝛽. E) ELISA for the quantification of IL-6 to assess regeneration of the OoC models after the treatment with an anti-inflammatory drug (baicalein). N = 3 independent experiments in separate plates.
Human Chondrocytes, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/Human+Chondrocytes/Human+Chondrocytes%3A+HC/pmc13087214-209-4-14
Average 94 stars, based on 1 article reviews
human chondrocytes - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

93
Innoprot Inc general cell culture rimary human articular cartilage derived chondrocytes
Figure 5. Healthy and pathological cartilage and tendon-on-a-chip models. A) Schematic representation of the OoC configuration to generate healthy and pathological musculoskeletal models. Specific cells are embedded within a representative matrix. This OoC further allows the perfusion of bioactive compounds. B) Alamar blue assay indicating the increase cell activity and C) Brightfield images with culture time when using tenocytes and <t>chondrocytes.</t> D) Brightfield and immunofluorescence images of the cells embedded within the matrix before and after the treatment with IL-1𝛽. E) ELISA for the quantification of IL-6 to assess regeneration of the OoC models after the treatment with an anti-inflammatory drug (baicalein). N = 3 independent experiments in separate plates.
General Cell Culture Rimary Human Articular Cartilage Derived Chondrocytes, supplied by Innoprot Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/Human+Chondrocytes/Human+Chondrocytes-articular/pm42872559-249-3-16
Average 93 stars, based on 1 article reviews
general cell culture rimary human articular cartilage derived chondrocytes - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
MedChemExpress nc sirna
a Schematic of experimental groups: fibroblasts derived from Adjacent, Control, and Niche tissues were treated with recombinant human CTGF (rhCTGF). b Western blot analysis of Collagen I and III in fibroblasts following rhCTGF treatment. c Schematic of transcriptomic analysis in human uterine fibroblasts (HUFs) with modulated LRP1 expression under rhCTGF stimulation. d Collagen I and III expression in HUFs transfected with control <t>siRNA</t> (siNC) or LRP1 siRNA (siLRP1) and stimulated with rhCTGF. e Volcano plot showing differentially expressed genes (DEGs) between rhCTGF-treated siNC and siLRP1 HUFs. f GO analysis indicating suppression of ERK and WNT pathways in LRP1-silenced, rhCTGF-treated HUFs. g Western blot of phosphorylated ERK in siNC- or siLRP1-transfected HUFs treated with rhCTGF. h Phospho-ERK levels in Adjacent, Control, and Niche fibroblasts treated with rhCTGF. i Western blot analysis of Collagen I, Collagen III, and phospho-β-catenin in HUFs transfected with siNC or siLRP1 and treated with rhCTGF in combination with PD98059 (MEK1 inhibitor) or PAF-C16 (ERK1/2 activator). j Collagen I, Collagen III, and phospho-β-catenin expression in Adjacent, Control, and Niche fibroblasts treated with rhCTGF with or without PD98059 or PAF-C16. All in vitro experiments are performed in three independent replicates. Adjacent, adjacent myometrium tissue of niche; Control, well-healed cesarean scar tissue; Niche, niche tissue; HUF, human uterine fibroblasts; siNC, <t>NC-siRNA;</t> siLRP1, LRP1-siRNA. Source data are provided as a Source Data file. Created in BioRender. He, C. (2025) https://BioRender.com/krpej6u --.
Nc Sirna, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/Human+Chondrocytes/CCN2%2FCTGF%2C+Human/pmc13066582-331-10-25
Average 94 stars, based on 1 article reviews
nc sirna - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

90
ATCC human chondrocyte cell line
a Schematic of experimental groups: fibroblasts derived from Adjacent, Control, and Niche tissues were treated with recombinant human CTGF (rhCTGF). b Western blot analysis of Collagen I and III in fibroblasts following rhCTGF treatment. c Schematic of transcriptomic analysis in human uterine fibroblasts (HUFs) with modulated LRP1 expression under rhCTGF stimulation. d Collagen I and III expression in HUFs transfected with control <t>siRNA</t> (siNC) or LRP1 siRNA (siLRP1) and stimulated with rhCTGF. e Volcano plot showing differentially expressed genes (DEGs) between rhCTGF-treated siNC and siLRP1 HUFs. f GO analysis indicating suppression of ERK and WNT pathways in LRP1-silenced, rhCTGF-treated HUFs. g Western blot of phosphorylated ERK in siNC- or siLRP1-transfected HUFs treated with rhCTGF. h Phospho-ERK levels in Adjacent, Control, and Niche fibroblasts treated with rhCTGF. i Western blot analysis of Collagen I, Collagen III, and phospho-β-catenin in HUFs transfected with siNC or siLRP1 and treated with rhCTGF in combination with PD98059 (MEK1 inhibitor) or PAF-C16 (ERK1/2 activator). j Collagen I, Collagen III, and phospho-β-catenin expression in Adjacent, Control, and Niche fibroblasts treated with rhCTGF with or without PD98059 or PAF-C16. All in vitro experiments are performed in three independent replicates. Adjacent, adjacent myometrium tissue of niche; Control, well-healed cesarean scar tissue; Niche, niche tissue; HUF, human uterine fibroblasts; siNC, <t>NC-siRNA;</t> siLRP1, LRP1-siRNA. Source data are provided as a Source Data file. Created in BioRender. He, C. (2025) https://BioRender.com/krpej6u --.
Human Chondrocyte Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/Human+Chondrocytes/CHON-002%3B+Chondrocyte%3B+Human/pm28035387-38-1-19
Average 90 stars, based on 1 article reviews
human chondrocyte cell line - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

94
Cell Applications Inc chondrocyte basal medium
ARG098 cytotoxicity to human <t>chondrocytes</t> . (A) ARG098 binding activity to human chondrocytes was assessed by flow cytometory. The white area is stained with human IgM and the black area is stained with ARG098. (B) RA synoviocytes pretreated with anti-Fas neutralizing antibody clone SM1/23. (C) Representative cell viability of human chondrocytes following ARG098 treatment (Experiment 1: from 0.1 to 1000 ng/mL, Experiment 2: from 1 to 100 μg/mL) versus untreated condition, as measured by the WST assay. Black circles and black triangles, ARG098; white circles and white triangles, human IgM. Each point represents mean ± SEM (n = 5).
Chondrocyte Basal Medium, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/Human+Chondrocytes/Human+Chondrocyte+Differentiation+Medium/pmc03161399-27-25-36
Average 94 stars, based on 1 article reviews
chondrocyte basal medium - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Cell Applications Inc oa hoacs
ARG098 cytotoxicity to human <t>chondrocytes</t> . (A) ARG098 binding activity to human chondrocytes was assessed by flow cytometory. The white area is stained with human IgM and the black area is stained with ARG098. (B) RA synoviocytes pretreated with anti-Fas neutralizing antibody clone SM1/23. (C) Representative cell viability of human chondrocytes following ARG098 treatment (Experiment 1: from 0.1 to 1000 ng/mL, Experiment 2: from 1 to 100 μg/mL) versus untreated condition, as measured by the WST assay. Black circles and black triangles, ARG098; white circles and white triangles, human IgM. Each point represents mean ± SEM (n = 5).
Oa Hoacs, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/Human+Chondrocytes/Human+Chondrocytes%3A+Osteoarthritis%3A+HC-OA/pmc12470037-206-5-7
Average 94 stars, based on 1 article reviews
oa hoacs - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

Image Search Results


Microfluidic platform and chip layout for dynamic chondrocyte culture under gravity‐driven flow. (A) Photograph of the microfluidic chip with reservoirs filled with culture medium, illustrating the assembled device used for experiments. (B) Schematic representation of the microfluidic chip layout showing an array of 24 culture units. Each unit comprises two culture medium reservoirs connected by four microchannels with varying width and height, subdivided into regions I–III to generate spatial gradients of fluid shear stress under gravity‐driven flow conditions.

Journal: Current Protocols

Article Title: A Gravity‐driven Microfluidic Platform for High‐throughput Culture and Inflammatory Stimulation of Human Articular Chondrocytes

doi: 10.1002/cpz1.70489

Figure Lengend Snippet: Microfluidic platform and chip layout for dynamic chondrocyte culture under gravity‐driven flow. (A) Photograph of the microfluidic chip with reservoirs filled with culture medium, illustrating the assembled device used for experiments. (B) Schematic representation of the microfluidic chip layout showing an array of 24 culture units. Each unit comprises two culture medium reservoirs connected by four microchannels with varying width and height, subdivided into regions I–III to generate spatial gradients of fluid shear stress under gravity‐driven flow conditions.

Article Snippet: Dulbecco's phosphate‐buffered saline (DPBS) (Gibco, cat. no. 14190144) Ethanol (96%) Human Fibronectin (Corning, cat. no. 356008) Human Collagen type IV (Sigma‐Aldrich, cat. no. 5533) Chondrocyte growth medium (HC Growth Medium, Cell Applications, cat. no. 411‐500) PDMS microfluidic chips (24‐unit gravity‐driven design, FinnAdvance) Rocker platform (AKITA rocker, FinnAdvance or equivalent) UV‐C sterilization system Micropipettes and sterile filtered tips CO 2 incubator (37°C, 5% CO 2 ) Biosafety cabinet (Class II) Stereomicroscope

Techniques: Shear

Expected cellular responses of human articular chondrocytes under dynamic culture and IL‑1β‐induced inflammatory conditions. Representative results illustrate chondrocyte morphology, viability, extracellular matrix (ECM) expression, metabolic activity, and inflammatory responses under gravity‐driven flow conditions. (A) Representative z‐projection fluorescence images of chondrocytes cultured for 21 days in microchannels coated with a fibronectin–collagen type IV mixture. Cells form aggregates and microtissue‐like structures across regions I–III corresponding to increasing fluid shear stress levels. Cells are stained for F‐actin (red) and nuclei (DAPI, blue). (B) Representative Live/Dead fluorescence images showing time‐dependent viability and proliferation of chondrocytes cultured under dynamic conditions on days 3, 7, 14, and 21 (control), compared with IL‑1β‐stimulated cultures on day 21 (1 and 10 ng/ml, applied from day 15 to day 21). Control cultures show progressive formation of compact microtissue‐like aggregates (white arrows), whereas IL‑1β stimulation results in disrupted aggregates (yellow arrows). Green: calcein‐AM (live cells); red: ethidium homodimer‐1 (dead cells). (C) Representative z‐projection immunofluorescence images of ECM marker expression in region I after 21 days of culture, comparing control and IL‑1β‐stimulated samples. Images show merged fluorescence channels for collagen type II (green), aggrecan (red), and nuclei (DAPI, blue). (D–E) Quantification of corrected total cell fluorescence (CTCF) for collagen type II (D) and aggrecan (E) across regions I–III for control and IL‑1β‐stimulated cultures at day 21 (n = 44 cells per group). (F) Cell metabolic activity measured using a PrestoBlue assay for control and IL‑1β‐stimulated samples at day 21 ( n = 5 independent samples per group). (G–H) Quantification of inflammatory mediators in culture supernatant collected at day 21 using multiplex ELISA, including matrix metalloproteinases (MMP‐1, MMP‐2, MMP‐3, MMP‐7, MMP‐9, MMP‐13) and cytokines (IL‑1β, IL‑6, IL‑8) ( n = 3 independent samples per group). Values below the lower limit of quantification are indicated as <LLOQ. (I) Quantification of collagen type II fragments released into the culture medium at day 21, measured by ELISA ( n = 3 independent samples per group). All fluorescence images include a 100 µm scale bar, and white dashed lines indicate microchannel boundaries. Statistical analysis was performed using the Kruskal–Wallis test with Dunn's post hoc comparison (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; n.s., not significant). Conditions include control (no cytokine) and IL‑1β stimulation (1 and 10 ng/ml). Note: Panels are adapted from da Silva et al. , licensed under CC BY 3.0.

Journal: Current Protocols

Article Title: A Gravity‐driven Microfluidic Platform for High‐throughput Culture and Inflammatory Stimulation of Human Articular Chondrocytes

doi: 10.1002/cpz1.70489

Figure Lengend Snippet: Expected cellular responses of human articular chondrocytes under dynamic culture and IL‑1β‐induced inflammatory conditions. Representative results illustrate chondrocyte morphology, viability, extracellular matrix (ECM) expression, metabolic activity, and inflammatory responses under gravity‐driven flow conditions. (A) Representative z‐projection fluorescence images of chondrocytes cultured for 21 days in microchannels coated with a fibronectin–collagen type IV mixture. Cells form aggregates and microtissue‐like structures across regions I–III corresponding to increasing fluid shear stress levels. Cells are stained for F‐actin (red) and nuclei (DAPI, blue). (B) Representative Live/Dead fluorescence images showing time‐dependent viability and proliferation of chondrocytes cultured under dynamic conditions on days 3, 7, 14, and 21 (control), compared with IL‑1β‐stimulated cultures on day 21 (1 and 10 ng/ml, applied from day 15 to day 21). Control cultures show progressive formation of compact microtissue‐like aggregates (white arrows), whereas IL‑1β stimulation results in disrupted aggregates (yellow arrows). Green: calcein‐AM (live cells); red: ethidium homodimer‐1 (dead cells). (C) Representative z‐projection immunofluorescence images of ECM marker expression in region I after 21 days of culture, comparing control and IL‑1β‐stimulated samples. Images show merged fluorescence channels for collagen type II (green), aggrecan (red), and nuclei (DAPI, blue). (D–E) Quantification of corrected total cell fluorescence (CTCF) for collagen type II (D) and aggrecan (E) across regions I–III for control and IL‑1β‐stimulated cultures at day 21 (n = 44 cells per group). (F) Cell metabolic activity measured using a PrestoBlue assay for control and IL‑1β‐stimulated samples at day 21 ( n = 5 independent samples per group). (G–H) Quantification of inflammatory mediators in culture supernatant collected at day 21 using multiplex ELISA, including matrix metalloproteinases (MMP‐1, MMP‐2, MMP‐3, MMP‐7, MMP‐9, MMP‐13) and cytokines (IL‑1β, IL‑6, IL‑8) ( n = 3 independent samples per group). Values below the lower limit of quantification are indicated as

Article Snippet: Dulbecco's phosphate‐buffered saline (DPBS) (Gibco, cat. no. 14190144) Ethanol (96%) Human Fibronectin (Corning, cat. no. 356008) Human Collagen type IV (Sigma‐Aldrich, cat. no. 5533) Chondrocyte growth medium (HC Growth Medium, Cell Applications, cat. no. 411‐500) PDMS microfluidic chips (24‐unit gravity‐driven design, FinnAdvance) Rocker platform (AKITA rocker, FinnAdvance or equivalent) UV‐C sterilization system Micropipettes and sterile filtered tips CO 2 incubator (37°C, 5% CO 2 ) Biosafety cabinet (Class II) Stereomicroscope

Techniques: Morphology, Expressing, Activity Assay, Fluorescence, Cell Culture, Shear, Staining, Control, Immunofluorescence, Marker, Prestoblue Assay, Multiplex Assay, Enzyme-linked Immunosorbent Assay, Analysis, Comparison

Troubleshooting guide for gravity‐driven microfluidic  chondrocyte  culture

Journal: Current Protocols

Article Title: A Gravity‐driven Microfluidic Platform for High‐throughput Culture and Inflammatory Stimulation of Human Articular Chondrocytes

doi: 10.1002/cpz1.70489

Figure Lengend Snippet: Troubleshooting guide for gravity‐driven microfluidic chondrocyte culture

Article Snippet: Dulbecco's phosphate‐buffered saline (DPBS) (Gibco, cat. no. 14190144) Ethanol (96%) Human Fibronectin (Corning, cat. no. 356008) Human Collagen type IV (Sigma‐Aldrich, cat. no. 5533) Chondrocyte growth medium (HC Growth Medium, Cell Applications, cat. no. 411‐500) PDMS microfluidic chips (24‐unit gravity‐driven design, FinnAdvance) Rocker platform (AKITA rocker, FinnAdvance or equivalent) UV‐C sterilization system Micropipettes and sterile filtered tips CO 2 incubator (37°C, 5% CO 2 ) Biosafety cabinet (Class II) Stereomicroscope

Techniques:

Figure 5. Healthy and pathological cartilage and tendon-on-a-chip models. A) Schematic representation of the OoC configuration to generate healthy and pathological musculoskeletal models. Specific cells are embedded within a representative matrix. This OoC further allows the perfusion of bioactive compounds. B) Alamar blue assay indicating the increase cell activity and C) Brightfield images with culture time when using tenocytes and chondrocytes. D) Brightfield and immunofluorescence images of the cells embedded within the matrix before and after the treatment with IL-1𝛽. E) ELISA for the quantification of IL-6 to assess regeneration of the OoC models after the treatment with an anti-inflammatory drug (baicalein). N = 3 independent experiments in separate plates.

Journal: Advanced Materials Technologies

Article Title: Vertical Membrane‐Free Organ‐on‐a‐Chip for High‐Throughput In Vitro Studies and Drug Screening

doi: 10.1002/admt.202402080

Figure Lengend Snippet: Figure 5. Healthy and pathological cartilage and tendon-on-a-chip models. A) Schematic representation of the OoC configuration to generate healthy and pathological musculoskeletal models. Specific cells are embedded within a representative matrix. This OoC further allows the perfusion of bioactive compounds. B) Alamar blue assay indicating the increase cell activity and C) Brightfield images with culture time when using tenocytes and chondrocytes. D) Brightfield and immunofluorescence images of the cells embedded within the matrix before and after the treatment with IL-1𝛽. E) ELISA for the quantification of IL-6 to assess regeneration of the OoC models after the treatment with an anti-inflammatory drug (baicalein). N = 3 independent experiments in separate plates.

Article Snippet: To evaluate the effect of 5-FU on the organoid monolayer model, a range of 5-FU (F6627, Sigma-Aldrich) concentrations was introduced into the upper channel of the OoCs for 24 h. Chondrocyte Culture: Human-derived chondrocytes (C-12710, PromoCell) were cultured using the basal medium (C-27111, PromoCell) supplemented with SupplementMix (C-39635, PromoCell), and 100 U mL−1 penicillin and 100 μg mL−1 streptomycin (DE17-602F, Lonza).

Techniques: Alamar Blue Assay, Activity Assay, Enzyme-linked Immunosorbent Assay

a Schematic of experimental groups: fibroblasts derived from Adjacent, Control, and Niche tissues were treated with recombinant human CTGF (rhCTGF). b Western blot analysis of Collagen I and III in fibroblasts following rhCTGF treatment. c Schematic of transcriptomic analysis in human uterine fibroblasts (HUFs) with modulated LRP1 expression under rhCTGF stimulation. d Collagen I and III expression in HUFs transfected with control siRNA (siNC) or LRP1 siRNA (siLRP1) and stimulated with rhCTGF. e Volcano plot showing differentially expressed genes (DEGs) between rhCTGF-treated siNC and siLRP1 HUFs. f GO analysis indicating suppression of ERK and WNT pathways in LRP1-silenced, rhCTGF-treated HUFs. g Western blot of phosphorylated ERK in siNC- or siLRP1-transfected HUFs treated with rhCTGF. h Phospho-ERK levels in Adjacent, Control, and Niche fibroblasts treated with rhCTGF. i Western blot analysis of Collagen I, Collagen III, and phospho-β-catenin in HUFs transfected with siNC or siLRP1 and treated with rhCTGF in combination with PD98059 (MEK1 inhibitor) or PAF-C16 (ERK1/2 activator). j Collagen I, Collagen III, and phospho-β-catenin expression in Adjacent, Control, and Niche fibroblasts treated with rhCTGF with or without PD98059 or PAF-C16. All in vitro experiments are performed in three independent replicates. Adjacent, adjacent myometrium tissue of niche; Control, well-healed cesarean scar tissue; Niche, niche tissue; HUF, human uterine fibroblasts; siNC, NC-siRNA; siLRP1, LRP1-siRNA. Source data are provided as a Source Data file. Created in BioRender. He, C. (2025) https://BioRender.com/krpej6u --.

Journal: Nature Communications

Article Title: Role of CTGF-LRP1 in impaired healing of cesarean section incisions

doi: 10.1038/s41467-026-69747-9

Figure Lengend Snippet: a Schematic of experimental groups: fibroblasts derived from Adjacent, Control, and Niche tissues were treated with recombinant human CTGF (rhCTGF). b Western blot analysis of Collagen I and III in fibroblasts following rhCTGF treatment. c Schematic of transcriptomic analysis in human uterine fibroblasts (HUFs) with modulated LRP1 expression under rhCTGF stimulation. d Collagen I and III expression in HUFs transfected with control siRNA (siNC) or LRP1 siRNA (siLRP1) and stimulated with rhCTGF. e Volcano plot showing differentially expressed genes (DEGs) between rhCTGF-treated siNC and siLRP1 HUFs. f GO analysis indicating suppression of ERK and WNT pathways in LRP1-silenced, rhCTGF-treated HUFs. g Western blot of phosphorylated ERK in siNC- or siLRP1-transfected HUFs treated with rhCTGF. h Phospho-ERK levels in Adjacent, Control, and Niche fibroblasts treated with rhCTGF. i Western blot analysis of Collagen I, Collagen III, and phospho-β-catenin in HUFs transfected with siNC or siLRP1 and treated with rhCTGF in combination with PD98059 (MEK1 inhibitor) or PAF-C16 (ERK1/2 activator). j Collagen I, Collagen III, and phospho-β-catenin expression in Adjacent, Control, and Niche fibroblasts treated with rhCTGF with or without PD98059 or PAF-C16. All in vitro experiments are performed in three independent replicates. Adjacent, adjacent myometrium tissue of niche; Control, well-healed cesarean scar tissue; Niche, niche tissue; HUF, human uterine fibroblasts; siNC, NC-siRNA; siLRP1, LRP1-siRNA. Source data are provided as a Source Data file. Created in BioRender. He, C. (2025) https://BioRender.com/krpej6u --.

Article Snippet: Following transfection with LRP1 siRNA, NC siRNA, lrp1 siRNA or nc siRNA for 48 hours, the cells were subsequently incubated with rhCTGF (HY- P70106 , MCE), PD98059 (HY-12028, MCE), or C16-PAF (HY-108635, MCE) for 48 hours.

Techniques: Derivative Assay, Control, Recombinant, Western Blot, Expressing, Transfection, In Vitro

a Experimental timeline for the establishment and treatment of the rat uterine scar model. b Schematic illustration and gross anatomical image of the rat uterine scar model. c H&E staining of uterine horns on days 14 and 30 post-surgery across sham, PBS, and rhctgf-treated groups ( n = 8 uterine horns per group). Red arrows indicate scar repair sites. Scale bars = 500 μm. d Immunohistochemical staining for α-smooth muscle actin (α-SMA) at incision sites on days 14 and 30. Red arrows mark the repaired myometrial regions. Scale bars = 500 μm. The regenerating myometrium originated from residual tissue flanking the incision and appeared thin, irregular, and fragmented. e Masson’s trichrome staining assessing collagen deposition at incision sites on days 14 and 30. Scale bars = 200 μm. Quantitative analysis of collagen fiber area was performed. f , g Efficiency of lrp1 knockdown in rat uterine fibroblasts assessed at the mRNA level. RT-qPCR and Western blot analyses show Collagen I and III expression in fibroblasts transfected with nc-siRNA or lrp1-siRNA and treated with rhctgf. Data are shown as mean ± SEM. The p values were calculated using a two-tailed unpaired Student’s t -test. Source data are provided as a Source Data file. Created in BioRender. He, C. (2025) https://BioRender.com/krpej6u .

Journal: Nature Communications

Article Title: Role of CTGF-LRP1 in impaired healing of cesarean section incisions

doi: 10.1038/s41467-026-69747-9

Figure Lengend Snippet: a Experimental timeline for the establishment and treatment of the rat uterine scar model. b Schematic illustration and gross anatomical image of the rat uterine scar model. c H&E staining of uterine horns on days 14 and 30 post-surgery across sham, PBS, and rhctgf-treated groups ( n = 8 uterine horns per group). Red arrows indicate scar repair sites. Scale bars = 500 μm. d Immunohistochemical staining for α-smooth muscle actin (α-SMA) at incision sites on days 14 and 30. Red arrows mark the repaired myometrial regions. Scale bars = 500 μm. The regenerating myometrium originated from residual tissue flanking the incision and appeared thin, irregular, and fragmented. e Masson’s trichrome staining assessing collagen deposition at incision sites on days 14 and 30. Scale bars = 200 μm. Quantitative analysis of collagen fiber area was performed. f , g Efficiency of lrp1 knockdown in rat uterine fibroblasts assessed at the mRNA level. RT-qPCR and Western blot analyses show Collagen I and III expression in fibroblasts transfected with nc-siRNA or lrp1-siRNA and treated with rhctgf. Data are shown as mean ± SEM. The p values were calculated using a two-tailed unpaired Student’s t -test. Source data are provided as a Source Data file. Created in BioRender. He, C. (2025) https://BioRender.com/krpej6u .

Article Snippet: Following transfection with LRP1 siRNA, NC siRNA, lrp1 siRNA or nc siRNA for 48 hours, the cells were subsequently incubated with rhCTGF (HY- P70106 , MCE), PD98059 (HY-12028, MCE), or C16-PAF (HY-108635, MCE) for 48 hours.

Techniques: Staining, Immunohistochemical staining, Knockdown, Quantitative RT-PCR, Western Blot, Expressing, Transfection, Two Tailed Test

ARG098 cytotoxicity to human chondrocytes . (A) ARG098 binding activity to human chondrocytes was assessed by flow cytometory. The white area is stained with human IgM and the black area is stained with ARG098. (B) RA synoviocytes pretreated with anti-Fas neutralizing antibody clone SM1/23. (C) Representative cell viability of human chondrocytes following ARG098 treatment (Experiment 1: from 0.1 to 1000 ng/mL, Experiment 2: from 1 to 100 μg/mL) versus untreated condition, as measured by the WST assay. Black circles and black triangles, ARG098; white circles and white triangles, human IgM. Each point represents mean ± SEM (n = 5).

Journal: BMC Musculoskeletal Disorders

Article Title: ARG098, a novel anti-human Fas antibody, suppresses synovial hyperplasia and prevents cartilage destruction in a severe combined immunodeficient-HuRAg mouse model

doi: 10.1186/1471-2474-11-221

Figure Lengend Snippet: ARG098 cytotoxicity to human chondrocytes . (A) ARG098 binding activity to human chondrocytes was assessed by flow cytometory. The white area is stained with human IgM and the black area is stained with ARG098. (B) RA synoviocytes pretreated with anti-Fas neutralizing antibody clone SM1/23. (C) Representative cell viability of human chondrocytes following ARG098 treatment (Experiment 1: from 0.1 to 1000 ng/mL, Experiment 2: from 1 to 100 μg/mL) versus untreated condition, as measured by the WST assay. Black circles and black triangles, ARG098; white circles and white triangles, human IgM. Each point represents mean ± SEM (n = 5).

Article Snippet: The sources of the other materials used in this study are as follows: human IgM was obtained from ICN Biomedicals Inc. (Aliso Viejo, CA, USA), chondrocyte basal medium supplemented with chondrocyte growth supplement was obtained from Cell Applications, Inc. (San Diego, CA, USA), and the neutralizing antibody anti-human APO-1/Fas (SM1/23) was obtained from Bender Medsystems GmbH (Vienna, Austria).

Techniques: Binding Assay, Activity Assay, Staining, WST Assay